Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Oct;76(4):461-471.
doi: 10.1097/FJC.0000000000000871.

The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis

Marie Barrientos-Regala  1 , Renelene A Macabeo  1 , Rosemarie Ramirez-Ragasa  1 , Noemi S Pestaño  1 , Felix E R Punzalan  1   2 , Bernadette Tumanan-Mendoza  1   3 , Rafael R Castillo  1   4   5
Affiliations
Meta-Analysis

The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis

Marie Barrientos-Regala et al. J Cardiovasc Pharmacol. 2020 Oct.

Abstract

Increased uric acid levels have been known to be associated with different cardiovascular and renal diseases. Over the past few years, several studies have examined the role of urate-lowering therapy (ULT) in hypertension and major adverse cardiac events (MACE) and suggest a potential role of elevated serum uric acid as an independent cardiovascular risk factor. This meta-analysis was done to determine the association of 2 ULTs commonly used in clinical practice (febuxostat vs. allopurinol) on hypertension and MACE and resolve the conflicting results of the outcomes of earlier studies. Randomized controlled trials comparing febuxostat versus allopurinol published with outcomes on blood pressure, all-cause mortality, myocardial infarction (MI), and stroke were searched through PubMed, Google Scholar, and Cochrane database. A total of 10 studies were subsequently included in the meta-analysis. Pooled analysis of the mean differences (MD) were done for the outcomes on blood pressure (systolic and diastolic) and risk ratios (RRs) for the outcomes on MACE with corresponding 95% confidence intervals (CIs). Pooled analysis of studies on hyperuricemic patients showed that febuxostat 40 mg has no significant difference compared with allopurinol 100/300 mg with respect to diastolic (MD, -0.56 with 95% CI of -4.28 to 3.15) and systolic blood pressure (MD, 0.30 with 95% CI of -3.33 to 3.93). No significant differences were also noted on all-cause mortality (RR, 1.18 with 95% CI of 0.99-1.41), MI (RR, 0.92 with 95% CI of 0.72-1.18), and stroke (RR, 1.05 with 95% CI of 0.77-1.43). The results of this meta-analysis showed that the 2 ULTs (febuxostat vs. allopurinol) have no significant association with respect to blood pressure among adult patients with hyperuricemia. No significant association was also noted of either ULT with all-cause mortality, MI, and stroke.

PubMed Disclaimer

References

    1. Min L, Xiaolan H, Yingli F, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality: a systematic review and dose-response meta-analysis. Sci Rep. 2016;6:19520.
    1. World Health Organization. A global brief on hypertension. 2013. Available at: https://www.who.int/cardiovascular_diseases/publications/global_brief_hy.... Accessed September 1, 2017.
    1. Sison J. Presyon 3—an update on hypertension prevalence in the Philippines. Philippine Heart Association, 44th Annual Convention and Scientific Meeting; May 29–31, 2013; Manila, Philippines.
    1. Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA Study. Hypertension. 2000;36:1072–1078.
    1. Li-Yu J, Salido EO, Manahan S, et al. Clinical practice guidelines for the management of gout. Phil J Intern Med. 2008;6:165–173.

MeSH terms